average weight loss with glp-1 Research Recap: Access & Clinical Outcomes for Obesity Treatment | Calibrate What Happens When You Start

(Graphic: Business Wire) Hims Hers has been collecting data on access challenges across GLP-1s since the beginning of September

This once-weekly treatment supports metabolic balance as part of a structured 3-month care plan

Currently, there are ten classes of orally available pharmacological agents to treat T2DM: 1) sulfonylureas, 2) meglitinides, 3) metformin (a biguanide), 4) thiazolidinediones (TZDs), 5) alpha glucosidase inhibitors, 6) dipeptidyl peptidase IV (DPP-4) inhibitors, 7) bile acid sequestrants, 8) dopamine agonists, 9) sodium-glucose transport protein 2 (SGLT2) inhibitors and 10) oral glucagon like peptide 1 (GLP-1) receptor agonists

Explore the transformative impact of GLP-1 medications on consumer behavior, food trends, and beyond

Healthcare leaders should: 1 : Consider whether post-overdose follow-up programs should include screening for obesity, diabetes, and potential GLP-1 eligibility

A4M - American Academy of Anti-Aging Medicine